Bluejay Therapeutics to Present at EASL Congress 2024

Bluejay Therapeutics recently announced they will present findings from their ongoing Phase 2 trial of BJT-778, an anti-HBsAg monoclonal antibody, at the European Association for the Study of the Liver (EASL) conference in Milan from June 5-8. This investigational antibody aims to treat chronic hepatitis D (CHD) by targeting the hepatitis B surface antigen. Besides the Phase 2 data, the company will showcase several posters detailing the preclinical profile, mechanisms of action, and safety of BJT-778 in healthy volunteers.

The EASL conference will feature four primary presentations from Bluejay Therapeutics. A key late-breaking poster will highlight the safety, tolerability, and antiviral efficacy of BJT-778 in the Phase 2 study focusing on chronic hepatitis delta virus (HDV). Additional presentations will delve into the pharmacokinetics and safety profile of BJT-778 in healthy volunteers, its preclinical characteristics including its affinity for HBsAg and neutralizing activity against hepatitis B and D viruses, and its immunomodulatory potential which could enhance antiviral T cell functions, thereby aiding in the clearance of HBV infection.

The scheduled presentations are as follows:

1. Late-Breaker Poster Presentation: Phase 2
- Title: Rapid reductions of HDV RNA and ALT with the monoclonal antibody, BJT-778: results from a phase 2 study (Abstract #LBP-001)
- Date: Wednesday, June 5 at 8:30 am CEST
- Presenter: Kosh Agarwal, M.D., Institute of Liver Studies, King's College Hospital, London, UK

2. Poster Presentation: Phase 1
- Title: Safety, tolerability, and pharmacokinetics of BJT-778, a monoclonal antibody for treatment of chronic hepatitis B and chronic hepatitis D, following single ascending doses in healthy volunteers (Abstract #WED-374)
- Date: Wednesday, June 5 at 8:30 am CEST
- Presenter: Edward Gane, M.D., University of Auckland, New Zealand

3. Poster Presentation: Preclinical
- Title: Characterization of BJT-778, an anti-HBsAg neutralizing monoclonal antibody for treatment of hepatitis B virus and hepatitis D virus infections (Abstract #WED-366)
- Date: Wednesday, June 5 at 8:30 am CEST
- Presenter: Hilario Ramos, Ph.D., Bluejay Therapeutics

4. Poster Presentation: Preclinical
- Title: Uptake and T cell stimulation by anti-HBs monoclonal antibody BJT-778-rHBsAg immune complexes (Abstract #SAT-536)
- Date: Saturday, June 8 at 8:30 am CEST
- Presenter: Loghman Salimzadeh, Ph.D., Schwartz-Reisman Liver Research Centre, University Health Network, Toronto, Ontario, Canada

BJT-778, a fully human IgG1 monoclonal antibody, shows high potency against the hepatitis B surface antigen. It neutralizes and clears hepatitis B and D virions and depletes HBsAg-containing particles, which may reconstitute antiviral immunity and contribute to a functional cure for chronic hepatitis B (CHB). The antibody's preclinical safety and efficacy render it an excellent candidate for combination therapies with existing and emerging treatments for CHB and CHD. Currently, BJT-778 is under evaluation for treating CHD and as a potential functional cure for chronic HBV.

Bluejay Therapeutics is a private biopharmaceutical company dedicated to developing treatments for viral and liver diseases. Their leading program, BJT-778, is under development for both chronic HBV and HDV. Besides BJT-778, Bluejay is advancing other innovative programs for chronic HBV, including a proprietary TLR9 agonist (Cavrotolimod) and a liver-targeted transcript inhibitor (BJT-628), aiming for higher rates of functional cure.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!